Zenas BioPharma, Inc.
ZBIO
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.1B
$32.88
▼ -0.12%
P/E
-3.42
Mkt Cap
$2.1B
52-Wk Range
$13.50–$44.60
52-Week Range
$13.50 - $44.60
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 52.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Bifunctional monoclonal antibody platform with dual mechanism of action
- Diversified pipeline targeting multiple high-prevalence autoimmune diseases
- Experienced management team with deep immunology and drug development expertise
- Strategic focus on underserved patient populations with significant unmet medical needs
Bear Case
1 risk
- Low volatility (beta -1.0).
Growth
Stable outlook
Clinical trial progression and regulatory milestones for obexelimab across multiple indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+86.7% over 3m
Quality
Below
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying ZBIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 12, 2026
Reported EPS of -$1.77 vs -$1.12 consensus (-58.0% surprise). Revenue of $1.0M vs $15.0M expected (-93.3%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-58.0%
Revenue trend · last 8Q
—
—
—
—
—
-100%
-100%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$5.0M
$10.0M
$0
$0
$0
$0
$1.0M
Margins · last 8Q
Gross
100.0%
Profit
-11145.6%
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
—
Latest: Citi · Jun 3, 2026
vs Industry
How ZBIO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related